BioCardia Inc. (BCDA)
2.18
-0.07 (-3.11%)
At close: Jan 14, 2025, 3:58 PM
2.16
-0.94%
After-hours Jan 14, 2025, 03:59 PM EST
undefined% (undefined)
| Bid | 0.88 |
| Market Cap | 10.00M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.03 |
| PE Ratio (ttm) | -0.54 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.41 |
| Volume | 74,327 |
| Avg. Volume (20D) | 49,731 |
| Open | 2.26 |
| Previous Close | 2.25 |
| Day's Range | 2.11 - 2.36 |
| 52-Week Range | 1.63 - 9.90 |
| Beta | undefined |
About BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 1996
Employees 16
Stock Exchange NASDAQ
Ticker Symbol BCDA
Website https://www.biocardia.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BCDA stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 1046.58% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
BioCardia Inc. is scheduled to release its earnings on Mar 26, 2025,
during market hours.
Analysts project revenue of $20.00K, reflecting a 53.85% YoY growth and earnings per share of -0.87, making a -35.56% decrease YoY.
Analysts project revenue of $20.00K, reflecting a 53.85% YoY growth and earnings per share of -0.87, making a -35.56% decrease YoY.
2 months ago ·
Source
-14.04%
BioCardia shares are trading higher. The company r...
Unlock content with
Pro Subscription
3 months ago ·
Source
+10.39%
BioCardia shares are trading higher after the company announced it regained compliance with the Nasdaq.
